A group from Faculty of Biology, University of Freiburg, 79104 Freiburg, Germany, etc. has reported about a bispecific lectibody boosting T cell cytotoxicity towards Gb3-positive cancer cells.
https://www.mdpi.com/2073-4409/12/14/1896
A lectibody, comprised of a dimeric fragment of the Shiga toxin B-subunit (StxB) and the human CD3 antibody（clone No. UCHT1）fragment, was produced in E. coli and purified via Ni-NTA affinity chromatography. The StxB-scFv UCHT1 lectibody has bispecificity to T-cells and Gb3-positive cancer cells. The Shiga toxin B-subunit (StxB) can selectively target Gb3-positive cancer cells, and cytotoxic T cells are activated via UCFT1.
In this paper, it was shown that the lectibody could induce the killing of up to 80% of Gb3-overexpressing cancer cells in haemorrhagic and solid tumours.